Granules Quarterly Results for Trading Insights
In Mar 2026, Granules (GRANULES) reported revenue ₹1,482 Cr and net profit ₹202 Cr — revenue +20.5% YoY. For annual financials, live price and key ratios, visit Granules screener.
GRANULES Quarterly Results — Revenue, Profit & EPS Highlights
Granules latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore GRANULES share price charts to track price trends across different timeframes.
- Revenue of ₹1,482 Cr in Mar 2026 (+14.5% vs Sept 2025, +20.5% vs Mar 2025)
- Net Profit of ₹202 Cr in Mar 2026 (+54.2% vs Sept 2025, +32.9% vs Mar 2025)
- EBITDA of ₹364 Cr in Mar 2026 (+32.4% vs Sept 2025)
- Operating Margin of 23.0% in Mar 2026 (+2.0pp vs Sept 2025)
- Earnings Per Share of ₹8.23 in Mar 2026 (+53.0% vs Sept 2025)
Granules Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GRANULES quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,482 | 1,294 | 1,230 | 1,225 | 1,374 | 14.5% | 20.5% |
| Net Profit (₹ Cr) | 202 | 131 | 152 | 113 | 150 | - | - |
| EBITDA (₹ Cr) | 364 | 275 | 284 | 236 | 295 | - | - |
| EPS (₹) | 8.23 | 5.38 | 6.27 | 4.64 | 6.19 | - | - |
| Operating Margin (%) | 23.0% | 21.0% | 21.0% | 18.0% | 22.0% | - | - |
GRANULES Share Price Trend — 1-Year Movement Across Quarterly Results
Granules 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with GRANULES fundamental valuation to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GRANULES vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Granules latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹443,373.10 Cr | 1863.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 143.3 |
|
Divis Laboratories
Sept 2025 |
₹178,235.60 Cr | 6921.5 | 2,860 | 689 | +7.1% | - | 24.1% | 266.5 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹145,389.39 Cr | 4403.9 | 3,219 | 591 | +11.3% | - | 18.4% | 251.1 |
|
Cipla
Mar 2026 |
₹107,240.96 Cr | 1436.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹105,607.38 Cr | 1303.6 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 491.9 |
All amounts in ₹ Crores